The Biosimilar Boom and the Coming Humira Price War (Video)
Drug Channels
SEPTEMBER 7, 2022
As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. That’s when Humira, the best-selling drug in the U.S., will face multiple biosimilar competitors. d/b/a Drug Channels Institute.
Let's personalize your content